Switzerland· 68844004
Alhemo 300 mg/3 ml, Injektionslösung im Fertigpen
A other systemic hemostatics product containing concizumabum, registered in Switzerland by Novo Nordisk Pharma AG and dispensed under Swissmedic category A. The same ATC class is registered in 3 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Concizumabum is registered in 3 of 19 countries.
Countries holding a registration under ATC B02BX (other systemic hemostatics), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 3 of them publish a price we can compare per daily dose
Concizumabum · ATC B02BX
3 / 19 countries
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- concizumabum
- Manufacturer
- Novo Nordisk Pharma AG
- Country
- Switzerland (CH)
- ATC code
- B02BX
- ATC class
- Other systemic hemostatics
- Swissmedic category
- A
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Concizumabum in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaALHEMONovo Nordisk A/S, Bagsvaerd
- SpainALHEMO 150 MG/1,5 ML SOLUCION INYECTABLE EN PLUMA PRECARGADANovo Nordisk A/S
- SwedenAlhemo 150 mg/1,5 ml Injektionsvätska, lösning i förfylld injektionspennaNovo Nordisk A/S
- BelgiumAlhemo 150 mg/1.5 mlNovo Nordisk
- IcelandAlhemoNovo Nordisk A/S*
- PolandAlhemoNovo Nordisk A/S
- IrelandAlhemo 15 mg/1.5 mL solution for injection in pre-filled penNovo Nordisk A/S
- NetherlandsAlhemo 15 mg/1,5 ml oplossing voor injectie in een voorgevulde penNovo Nordisk A.S.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Alhemo
- Norway · Alhemo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e7bbc227-8d34-4798-be82-754430d6097b GET /v1/drugs/e7bbc227-8d34-4798-be82-754430d6097b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Biotechnologika"
}See everything about concizumabum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.